Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022

SELL
$10.6 - $13.28 $18,656 - $23,372
-1,760 Closed
0 $0
Q1 2022

May 17, 2022

SELL
$10.37 - $12.73 $14,082 - $17,287
-1,358 Reduced 43.55%
1,760 $21,000
Q4 2021

Feb 15, 2022

SELL
$10.21 - $15.27 $14,773 - $22,095
-1,447 Reduced 31.7%
3,118 $35,000
Q3 2021

Nov 12, 2021

SELL
$14.07 - $17.3 $23,257 - $28,596
-1,653 Reduced 26.58%
4,565 $67,000
Q2 2021

Jul 30, 2021

SELL
$16.62 - $18.94 $34,154 - $38,921
-2,055 Reduced 24.84%
6,218 $108,000
Q1 2021

May 07, 2021

BUY
$15.15 - $19.78 $1,742 - $2,274
115 Added 1.41%
8,273 $143,000
Q4 2020

Feb 12, 2021

BUY
$16.86 - $19.67 $1,702 - $1,986
101 Added 1.25%
8,158 $150,000
Q3 2020

Nov 16, 2020

SELL
$15.4 - $20.16 $8,978 - $11,753
-583 Reduced 6.75%
8,057 $140,000
Q2 2020

Aug 12, 2020

SELL
$18.24 - $21.45 $17,455 - $20,527
-957 Reduced 9.97%
8,640 $158,000
Q1 2020

May 15, 2020

BUY
$16.28 - $25.63 $18,070 - $28,449
1,110 Added 13.08%
9,597 $193,000
Q4 2019

Feb 14, 2020

BUY
$19.57 - $23.52 $17,260 - $20,744
882 Added 11.6%
8,487 $198,000
Q3 2019

Nov 14, 2019

BUY
$19.85 - $22.76 $8,436 - $9,673
425 Added 5.92%
7,605 $152,000
Q2 2019

Aug 14, 2019

BUY
$17.59 - $21.1 $36,446 - $43,719
2,072 Added 40.56%
7,180 $151,000
Q1 2019

May 15, 2019

BUY
$18.01 - $20.11 $26,636 - $29,742
1,479 Added 40.76%
5,108 $103,000
Q4 2018

Jan 31, 2019

BUY
$17.44 - $21.53 $23,230 - $28,677
1,332 Added 57.99%
3,629 $67,000
Q3 2018

Nov 15, 2018

BUY
$19.97 - $21.96 $12,621 - $13,878
632 Added 37.96%
2,297 $49,000
Q2 2018

Aug 22, 2018

SELL
$20.16 - $24.68 $3,064 - $3,751
-152 Reduced 8.37%
1,665 $36,000
Q2 2018

Aug 15, 2018

BUY
$20.16 - $24.68 $36,630 - $44,843
1,817 New
1,817 $36,000

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $6.06B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Advisors Asset Management, Inc. Portfolio

Follow Advisors Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.